Efficiency and Tolerability of Induction and Consolidation Therapy with Arsenic Trioxide/Bortezomib/Ascorbic Acid/Dexamethasone (ABCD) Regimen Compared to Bortezomib/Dexamethasone (BD) Regimen in Newly Diagnosed Myeloma Patients

PURPOSE: This study was aimed at comparing the efficacy and tolerability of an arsenic trioxide/bortezomib/ascorbic acid/dexamethasone (ABCD) regimen with efficacy and tolerability of a bortezomib/dexamethasone (BD) regimen in patients with newly diagnosed myeloma. PATIENTS AND METHODS: Fifty-seven...

Descripción completa

Detalles Bibliográficos
Autores principales: Qian, Wensi, Wang, Li, Li, Pei, Hu, Yingwei, Wang, Qian, Yi, Ke, Wu, Min, Xu, Yu, Song, Jin, Chen, Pingping, Zhang, Hongdi, Ma, Jiexian, Xie, Yanhui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6980852/
https://www.ncbi.nlm.nih.gov/pubmed/32021455
http://dx.doi.org/10.2147/CMAR.S212455

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6980852/
https://www.ncbi.nlm.nih.gov/pubmed/32021455
http://dx.doi.org/10.2147/CMAR.S212455

Ejemplares similares